JPRN-UMIN000014750已完成未知
The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patients - The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patients
Hematology and Oncology, Mie University Hospital0 个研究点目标入组 10 人开始时间: 2014年8月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. drug allergy to T-DM1 or trastuzumab 2. uncontrollable infection and diabetes mellitus 3. bleeding tendency 4. not suitable for participation with any other reasons
研究者
相似试验
已完成
1 期
A Phase Ib study of Trastuzumab emtansine plus S-1 or Capecitabine in patients with previously trastuzumab treated metastatic breast cancerPatients with HER2-positive metastatic breast cancer that has progressed on trastuzumabJPRN-UMIN000018383St Marianna University School of Medicine20
已完成
不适用
A Study of Trastuzumab Emtansine in Patients With HER2-Positive, Recurrent Metastatic Non-Small Cell Lung CancerJPRN-UMIN000017709Okayama University Hospital30
进行中（未招募）
1 期
A study in HER2-positive breast cancer that has spread to other organs or tissues and has not responded to a course of anti-cancer treatment and a study in HER2-positive inoperable gastric cancer or gastric cancer that has spread to other organs or tissues.HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic gastric cancer.MedDRA version: 19.0Level: PTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001547-46-DEF. Hoffmann-La Roche Ltd.160
进行中（未招募）
1 期
A study in HER2-positive breast cancer that has spread and has not responded to a course of anti-cancer treatment and a study in HER2-positive gastric cancer that has spread and has not been treated with any chemotherapeutic agent before.HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic gastric cancer.MedDRA version: 17.1Level: PTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001547-46-GRF. Hoffmann-La Roche Ltd.235
进行中（未招募）
1 期
A study in HER2-positive breast cancer that has spread to other organs or tissues and has not responded to a course of anti-cancer treatment and a study in HER2-positive inoperable gastric cancer or gastric cancer that has spread to other organs or tissues.HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic gastric cancer.MedDRA version: 20.0Level: PTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001547-46-PTF. Hoffmann-La Roche Ltd.160